newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

ISELIN, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva